TNDM Advancing Diabetes Technology With Ultra-Rapid Acting Insulin The t:slim X2 insulin pump, equipped with Control-IQ AID technology, is recognized for its ability to improve diabetes management ...

The solution involves smart insulin that would come into action ... while another has been launched to find a ultra-fast acting variant. Dr Tim Heise, the vice-chair of the novel insulins ...

The initial therapeutic focus is diabetes, with three insulin-based products in development. Lead product is an ultra-rapid acting insulin, which the company hopes will outperform market rivals ...

A full-year 2024 trading update for Arecor Therapeutics shows revenue was up to £5.1million (2023: £4.6m) while cash and cash ...

Nova Minerals identifies new high-grade zone with samples up to 52.3 g/t at Estelle Gold and Critical Minerals Project ...

In the third quarter of 2024, t:slim X2 became compatible with Eli Lilly and Company’s Lyumjev — an ultra-rapid-acting insulin in the European Union. In addition, the company made a ...

(Alliance News) - Arecor Therapeutics PLC on Monday said its revenue increased in 2024 and said it is excited by the prospects of its "superior insulin candidate". The Cambridgeshire, England-based ...

Arecor’s own lead product is an ultra-rapid acting insulin, which the company hopes will outperform market rivals from the likes of Eli Lilly, Sanofi and Novo Nordisk. Codenamed AT247 ...

Arecor's focus will now shift to high-value research and development opportunities, particularly in advancing its ultra-rapid acting insulin candidate, AT278, and its oral peptide delivery platform.

Arecor Therapeutics reported total full-year revenue of £5.1m in a trading update on Monday, up from £4.6m in 2023.

Cambridge biopharma company Arecor saw its cash pile more than halved in the year to December 31; it was down from £6.8 ...

ultra-rapid-acting insulin shown to be superior in patients with Type 1 and Type 2 diabetes. She also discussed their progress with a new oral GLP-1 formulation in collaboration with TRx ...